Lipocine, Inc. (LPCN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1156979,
    "name": "Lipocine, Inc.",
    "stock_name": "Lipocine, Inc.",
    "full_name": "Lipocine, Inc.",
    "name_url": "stocks-analysis/lipocine-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "3.10",
    "chg": -0.15,
    "chgp": "-4.62%",
    "dir": -1,
    "prev_price": "3.25",
    "mcapval": "15.79",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US53630X2036",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "33.37 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/lipocine-inc-1156979-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Lipocine, Inc. Hits 52-Week Low at $2.52 Amidst Declining Sales",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/lipocine-inc-hits-52-week-low-at-252-amidst-declining-sales-3674055",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/LipocineInc_priceRelatedfactors_3674055.png",
        "date": "2025-11-05 16:48:55",
        "description": "Lipocine, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company faces financial challenges, including a negative return on equity and a substantial drop in net sales. Institutional investor participation has also decreased, highlighting concerns about management efficiency."
      },
      {
        "title": "Lipocine, Inc. Stock Plummets to New 52-Week Low of $2.57",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/lipocine-inc-stock-plummets-to-new-52-week-low-of-257-3662009",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/LipocineInc_priceRelatedfactors_3662009.png",
        "date": "2025-10-31 16:24:32",
        "description": "Lipocine, Inc. has reached a new 52-week low, reflecting significant challenges in its financial performance. The company has seen a substantial decline in net sales and a negative return on equity, alongside a decrease in institutional investor participation, indicating a precarious financial situation in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Lipocine, Inc. Stock Plummets to New 52-Week Low of $2.65",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/lipocine-inc-stock-plummets-to-new-52-week-low-of-265-3574501",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/LipocineInc_priceRelatedfactors_3574501.png",
        "date": "2025-09-26 15:14:07",
        "description": "Lipocine, Inc. has reached a new 52-week low, reflecting a difficult year marked by a significant stock price decline. The company faces challenges with negative return on equity, a sharp drop in net sales, and consecutive quarterly losses, alongside reduced institutional investor participation."
      },
      {
        "title": "Lipocine, Inc. Hits New 52-Week Low at $2.68 Amid Declining Sales",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/lipocine-inc-hits-new-52-week-low-at-268-amid-declining-sales-3571349",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/LipocineInc_priceRelatedfactors_3571349.png",
        "date": "2025-09-25 16:49:07",
        "description": "Lipocine, Inc. has reached a new 52-week low, reflecting a difficult year marked by a significant decline in stock price and net sales. The company faces ongoing financial challenges, including negative returns on equity and reduced institutional investor participation, contributing to heightened market risk perceptions."
      },
      {
        "title": "Is Lipocine, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-lipocine-inc-technically-bullish-or-bearish-3547410",
        "imagepath": "",
        "date": "2025-09-20 19:54:46",
        "description": "As of 8 September 2025, the technical trend for Lipocine, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe and bearish signals from Bollinger Bands and KST. Daily moving averages also indicate a bearish trend. The Dow Theory shows a mildly bearish stance on the monthly timeframe, while the On-Balance Volume (OBV) presents a mildly bearish signal weekly but mildly bullish monthly. \n\nIn terms of performance, Lipocine has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -42.42% compared to the S&P 500's 12.22%, and a one-year return of -43.91% versus 17.14%...."
      },
      {
        "title": "Is Lipocine, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-lipocine-inc-overvalued-or-undervalued-3543793",
        "imagepath": "",
        "date": "2025-09-20 18:28:49",
        "description": "As of 8 May 2025, the valuation grade for Lipocine, Inc. has moved from fair to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued, particularly given its negative performance metrics and ratios. Key valuation ratios include a Price to Book Value of 0.88, an EV to EBIT of 0.42, and an EV to EBITDA of 0.43, which reflect significant concerns about its financial health and operational efficiency.\n\nIn comparison to peers, Lipocine's valuation is notably weaker; for instance, Lisata Therapeutics, Inc. has an EV to EBITDA of 0.1349, while Oncternal Therapeutics, Inc. stands at 0.3568. The stark contrast in these ratios highlights Lipocine's precarious position in the industry. Additionally, the company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -42.42% compared to the index's 12.22%, reinforcing the notion that Lipocin..."
      }
    ],
    "total": 11,
    "sid": "1156979",
    "stock_news_url": "https://www.marketsmojo.com/news/lipocine-inc-1156979"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Lipocine, Inc. Hits 52-Week Low at $2.52 Amidst Declining Sales

2025-11-05 16:48:55

Lipocine, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company faces financial challenges, including a negative return on equity and a substantial drop in net sales. Institutional investor participation has also decreased, highlighting concerns about management efficiency.

Lipocine, Inc. Stock Plummets to New 52-Week Low of $2.57

2025-10-31 16:24:32

Lipocine, Inc. has reached a new 52-week low, reflecting significant challenges in its financial performance. The company has seen a substantial decline in net sales and a negative return on equity, alongside a decrease in institutional investor participation, indicating a precarious financial situation in the Pharmaceuticals & Biotechnology sector.

Lipocine, Inc. Stock Plummets to New 52-Week Low of $2.65

2025-09-26 15:14:07

Lipocine, Inc. has reached a new 52-week low, reflecting a difficult year marked by a significant stock price decline. The company faces challenges with negative return on equity, a sharp drop in net sales, and consecutive quarterly losses, alongside reduced institutional investor participation.

Lipocine, Inc. Hits New 52-Week Low at $2.68 Amid Declining Sales

2025-09-25 16:49:07

Lipocine, Inc. has reached a new 52-week low, reflecting a difficult year marked by a significant decline in stock price and net sales. The company faces ongoing financial challenges, including negative returns on equity and reduced institutional investor participation, contributing to heightened market risk perceptions.

Is Lipocine, Inc. technically bullish or bearish?

2025-09-20 19:54:46

As of 8 September 2025, the technical trend for Lipocine, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe and bearish signals from Bollinger Bands and KST. Daily moving averages also indicate a bearish trend. The Dow Theory shows a mildly bearish stance on the monthly timeframe, while the On-Balance Volume (OBV) presents a mildly bearish signal weekly but mildly bullish monthly. In terms of performance, Lipocine has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -42.42% compared to the S&P 500's 12.22%, and a one-year return of -43.91% versus 17.14%....

Is Lipocine, Inc. overvalued or undervalued?

2025-09-20 18:28:49

As of 8 May 2025, the valuation grade for Lipocine, Inc. has moved from fair to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued, particularly given its negative performance metrics and ratios. Key valuation ratios include a Price to Book Value of 0.88, an EV to EBIT of 0.42, and an EV to EBITDA of 0.43, which reflect significant concerns about its financial health and operational efficiency. In comparison to peers, Lipocine's valuation is notably weaker; for instance, Lisata Therapeutics, Inc. has an EV to EBITDA of 0.1349, while Oncternal Therapeutics, Inc. stands at 0.3568. The stark contrast in these ratios highlights Lipocine's precarious position in the industry. Additionally, the company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -42.42% compared to the index's 12.22%, reinforcing the notion that Lipocin...

View All News